



PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete If Known Application Number 10/510361 Filing Date October 5, 2004 First Named Inventor Hubert Eng Art Unit N/A Examiner Name Not Yet Assigned Attorney Docket Number AREX-P01-015		
Sheet	1	of	1		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (#known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² -Number-Kind Code ³ (#known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
	BA	WO 01/85204	11-15-2001	AltaRex Corp.		
	BB	EP 553244B1	08-04-1993	Medarex, Inc.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ²
	CA	Avigan, "Dendritic cells: development, function and potential use for cancer immunotherapy," Blood Reviews 13: 51-64 (1999).				
	CB	Bjork, P., "Short Analytical Review: Development of Dendritic Cells and Their Use in Tumor Therapy," Clinical Immunology 92: 119-127 (1999).				
	CC	Coughlan et al., "Enhanced proliferation of CD4+ T cells induced by dendritic cells following antigen uptake in the presence of a specific antibody," Veterinary Immunology and Immunopathology 49: 321-330 (1996).				
	CD	Dhodapkar et al., "Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells," Journal of Clinical Investigation, 104:2, 173-180 (1999).				
	CE	Regnault et al., "Fcγ Receptor-mediated Induction of Dendritic Cell Maturation and Major Histocompatibility Complex Class I-restricted Antigen Presentation after Immune Complex Internalization," J. Exp. Med. 189:2, 371-380 (1999).				
	CF	Steinman, "The Dendritic Cell System And Its Role In Immunogenicity," Annu. Rev. Immunol. 9: 271-296 (1991).				
	CG	Timmerman et al., "Dendritic Cell Vaccines For Cancer Immunotherapy," Annu. Rev. Med. 50: 507-529 (1999).				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BD/

Examiner Signature	/Brad Duffy/	Date Considered	05/23/2008
9581933_1			